Physician profile
Zev E Carroll
NPI 1467491498
$9,596.89
in general payments reported to CMS, 2019-2025
43 companies · $791 in 2025
The $791 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,166 · 2020: $1,043 · 2021: $1,773 · 2022: $1,453 · 2023: $1,197 · 2024: $1,174 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,202.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,105.93 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $920.85 | 2019-2023 | Farxiga |
| Amgen INC. | $714.32 | 2019-2025 | Tepezza, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $660.24 | 2019-2022 | |
| Corcept Therapeutics | $604.66 | 2021-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $541.29 | 2019-2024 | Unithroid |
| Mannkind Corporation | $527.06 | 2019-2025 | Afrezza |
| Merck Sharp & Dohme LLC | $457.58 | 2019-2021 | |
| Abbvie INC. | $357.76 | 2019-2025 | Synthroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.51 | 2019-2024 | Cycloset |
| Xeris Pharmaceuticals, INC. | $295.97 | 2021-2024 | Recorlev |
| Lilly USA, LLC | $257.81 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Horizon Therapeutics Plc | $147.75 | 2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $121.56 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zev Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.